Analyzing Whether Pharmacogenetics in Psychiatric Patients with Polypharmacy Can Identify Increased Medication Adverse Effects and Improve Outcomes
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 18-006182
NCT ID: NCT03748355
Sponsor Protocol Number: 18-006182
About this study
The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- Ages 18 and older.
- Hospitalized on Generose 2E (Acute Care Psychiatry), 3E (Medical and Geriatric Psychiatry), or 3W (Mood Disorders Unit).
- A voluntary patient.
- Having 5 or more medications (scheduled or as needed) on their medication list.
- Ability to give informed consent.
- Patients with cognitive impairments such as moderate to severe dementia.
- Patients who do not communicate in English or cannot comprehend the rating scales used.
- Patients who have had pharmacogenetics testing performed within the previous 5 years.
- Patients who deny permission to communicate the PGx results with their outpatient provider.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Simon Kung, M.D.
Closed for enrollment
Publications are currently not available